Moderna delivers Canada’s first locally manufactured mRNA vaccines

All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada

Fermenta to sell environmental solutions business to its subsidiary

The entity will undertake the installation, operation, and maintenance of sewage treatment plants

Datavant partners with Indegene to power clinical trial recruitment

Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar

Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints

Novo Nordisk’s Wegovy delivered 16.6% weight loss

Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight

Bayer launches biotech innovation platform in China

Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks

Pete Pharma and FABRX announce strategic partnership

Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US

GSK to invest $30 billion in R&D, manufacturing in US over next 5 years

Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs